Medical Management of Late-stage Parkinson’s Disease – a Cross-sectional, Multinational Survey
Objective: To investigate disease characteristics and common drug treatment of late-stage Parkinsons’ disease (LSPD). Background: LSPD presents with disabling motor and non-motor symptoms, the latter…How large must a Parkinson’s disease trial be to detect pharmacogenomic interactions? Power benchmarks derived from the Exenatide PD3 clinical trial
Objective: To investigate whether genetic variation in the GLP1R gene modifies treatment response to the GLP1 agonist exenatide in the Exenatide-PD3 trial, and to characterise…Translational evaluation of CSF as a relevant compartment for assessing target engagement of therapeutic anti–α-syn antibodies.
Objective: To evaluate a translational free/total α-synuclein (α-syn) assay framework to quantify in vivo target engagement (TE) of anti–α-syn antibodies in preclinical models and to…Continuous subcutaneous levodopa infusion in advanced Parkinson’s disease: a descriptive real-world cohort study
Objective: To describe clinical characteristics, treatment indications, safety profile, and treatment persistence in patients with advanced PD treated with continuous subcutaneous levodopa infusion. Background: Continuous…Real-world variability in dosing of continuous subcutaneous foslevodopa/foscarbidopa infusion in advanced Parkinson’s disease: evidence from a single-center cohort
Objective: To evaluate dosing patterns, demographic characteristics, and safety outcomes in patients with advanced Parkinson's Disease (PD) treated with continuous subcutaneous foslevodopa/foscarbidopa infusion in routine…Real-World Clinical Experience With Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion In Advanced Parkinson’s Disease Patients With Mild Cognitive Impairment And History Of Psychosis
Objective: To describe the efficacy and safety of continuous subcutaneous infusion of foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson’s disease (aPD) in routine clinical practice, focusing on…Response to symptomatic therapy in Primary Brain Calcification: a cohort survey
Objective: To assess therapy response in a PBC cohort Background: Primary Brain Calcification (PBC) is a neurodegenerative disorder characterized by calcium deposition in the brain…Differential Effect of MAO-B Inhibitors in GBA1 Carriers with Parkinson’s Disease Women vs Men
Objective: To investigate the longitudinal impact of MAOIs on motor progression among Parkinson's disease (PD) patients carrying GBA1 mutations, with an emphasis on sex-stratified clinical…Modulation of Excitatory/Inhibitory Neurotransmission via Targeting GABAA-Gephyrin Signaling: Integrated In-Silico, In-Vitro, and In-Vivo Evidence in Parkinson’s Disease Models
Objective: To evaluate the neuroprotective potential of wogonin in modulating excitatory–inhibitory neurotransmission via GABAA receptor and gephyrin signaling in rat models of Parkinson’s disease (PD).…Polypharmacy and its Impact in Individuals with Parkinson’s Disease: Theory- and Data-Driven Approaches
Objective: The aim is to explore the relationship between high prescription drug use (polypharmacy), and its unintended effects on individuals with Parkinson’s Disease (PD). Background:…
- 1
- 2
- 3
- …
- 36
- Next Page »